Interleukin Genetics Announces Conference Call to Discuss Third Quarter 2016 Financial Results

WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. ILIU announced today that it will host a conference call and webcast on Tuesday, November 15, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2016.

A live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com. 

About Interleukin Genetics
Interleukin Genetics, Inc. ILIU develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics' lead products include its proprietary ILUSTRA™ Inflammation Management Program for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.